Please Wait.....
Report
Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-04-01 I 300 Pages I Allied Market Research
The radiopharmaceuticals market was valued at $5.2 billion in 2022, and is estimated to reach $13.7 billion by 2032, growing at a CAGR of 10.2% from 2023 to 2032. Radiopharmaceutical is defined as the radioactive drugs which are used to monitor, diagnose and treat a wide range of disease. The radiopharmaceuticals are widely used for therapeutic and diagnostic purposes. In therapeutic application, the radiopharmaceuticals are administered in some amount so that the proper therapeutic dose of radiation are delivered to specific disease sites. Meanwhile, in diagnostic procedures, the body is exposed to a small amount of radiation in order to observe the function of the organ. The radioactive drugs possess short half-lives; hence they must reach the patient for administration immediately after they manufacture.
The radiopharmaceuticals market is driven by the rise in prevalence of target disease such as cancer, neurological disease and cardiovascular disease, and increase in use of radiopharmaceutical in medical imaging. According to the World Cancer Research Fund International, in 2020, it was reported that around 18.1 million new cancer cases are diagnosed, globally. Radiopharmaceuticals use the radioactive substances to diagnose and treat cancer. Some of the radiopharmaceuticals that are used in diagnosis of cancer are Axumin, PYLARIFY, CERIANNA, Locametz, and Lymphoseek. In addition, the researchers also aims to develops novel radiopharmaceuticals agents, which is designed to deliver the radiation therapy specifically and directly to cancel cells. The surge in the demand for radiation therapy, and rise in number of diagnosis procedure for cancer and other target disease thus propel the growth of the market.
Furthermore, the radiopharmaceutical is used during the positron emission tomography (PET) imaging, in order to assist the examination of biological tissue. The increase in number of prostate, cardiac and amyloid imaging, surge the need for PET procedure. Increase in demand for medical imaging, surge the need for radiopharmaceuticals and boosts the growth of the radiopharmaceuticals market.Increase in the number of product approvals for radiopharmaceuticals fuels the growth of the market.
For instance, in March 2023, Telix Pharmaceuticals, a biotechnology company, announced the U.S Food and Drug Administration (FDA), approval for Illuccix. It is radiolabel with Ga 68 to form a radioactive diagnostic agent. It is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In addition, in March 2022, the U.S Food and Drug Administration (FDA), announced the approval of Pluvicto, for the treatment of adult patient with prostate cancer. Pluvicto, is the first PSMA-targeted radiopharmaceutical, contain lutetium Lu 177 vipivotide tetraxetan, radioisotopes.
In addition, increase in R&D activities in healthcare industry, propel the growth of the market. The Institute for Nuclear Sciences Applied to Health at the University of Coimbra, actively involved in the R&D activities to meet the present and future demand for application of diagnostic radiopharmaceuticals. Moreover, increase in the number of clinical trials on radiopharmaceuticals boosts the growth of the radiopharmaceuticals market. Furthermore, rise in investment for R&D activities in healthcare further boosts market growth. However, factors that hinder the market growth include side effect associated with the use of radiopharmaceutical such as nausea, vomiting, abdominal pain, and back pain.
On the other hand, the presence of radiopharmaceutical industry, increase in R&D activities for radiopharmaceuticals and growth potential in emerging markets are expected to create immense opportunities for radiopharmaceuticals during the forecast period.
The radiopharmaceuticals market is segmented on the basis of radioisotopes, application, type, end user and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. The others include Indium-111, Yttrium-90, Lutetium Lu-177, Copper-64, Carbon-14, Carbon-11, Strontium-89, Rubidium-82, Radium-223, Nitrogen-13, Molybdenum, Gallium-67, Thallium-201, and Xenon-133. On the basis of application, the market is bifurcated into cancer, cardiology and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutics. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. The others segment include diagnostic centers, and research institute.
On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and Rest of LAMEA).Major key players that operate in the global radiopharmaceuticals market are Cardinal Health Inc., Curium Pharma, Eli Lilly and Company, General Electric Company, Iso-Tex Diagnostics, Inc., Jubilant Pharmova Limited, Lantheus Holdings, Inc., Novartis AG, Siemens AG, and Bayer.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2022 to 2032 to identify the prevailing radiopharmaceuticals market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Iodine I
- Gallium 68
- Others
- Technetium 99m
- Fluorine 18
By Application
- Cancer
- Cardiology
- Others
By Type
- Diagnostic
- Therapeutic
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Bayer AG
- Cardinal Health Inc.
- Curium Pharma
- Eli Lilly and Company
- General Electric Company
- Iso-Tex Diagnostics, Inc
- Jubilant Pharmova Limited
- Lantheus Holdings, Inc.
- Novartis AG
- Siemens AG
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer, cardiovascular and neurological disease
3.4.1.2. Increase in demand for medical imaging
3.4.1.3. Increase in number of product approval for radiopharmaceuticals
3.4.2. Restraints
3.4.2.1. Side effect associated with radiopharmaceuticals
3.4.3. Opportunities
3.4.3.1. Presence of radiopharmaceutical industry
3.4.3.2. Increase in R&D activities for radiopharmaceuticals
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Technetium 99m
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Fluorine 18
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Iodine I
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Gallium 68
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiology
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Therapeutic
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals and clinics
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Medical Imaging centers
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Radioisotope
8.2.3. Market size and forecast, by Application
8.2.4. Market size and forecast, by Type
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Radioisotope
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Type
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Radioisotope
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Type
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Radioisotope
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by Type
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Radioisotope
8.3.3. Market size and forecast, by Application
8.3.4. Market size and forecast, by Type
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Radioisotope
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Type
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Radioisotope
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Type
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Radioisotope
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Type
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Radioisotope
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Type
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Radioisotope
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Type
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Radioisotope
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Type
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Radioisotope
8.4.3. Market size and forecast, by Application
8.4.4. Market size and forecast, by Type
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Radioisotope
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Type
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Radioisotope
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Type
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Radioisotope
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Type
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Radioisotope
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Type
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Radioisotope
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Type
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Radioisotope
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Type
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Radioisotope
8.5.3. Market size and forecast, by Application
8.5.4. Market size and forecast, by Type
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Radioisotope
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Type
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Radioisotope
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Type
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Radioisotope
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by Type
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Radioisotope
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by Type
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Curium Pharma
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. Cardinal Health Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. General Electric Company
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Iso-Tex Diagnostics, Inc
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.5. Lantheus Holdings, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Siemens AG
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Jubilant Pharmova Limited
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Novartis AG
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Bayer AG
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Eli Lilly and Company
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2022-2032 ($MILLION)
TABLE 03. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2022-2032 ($MILLION)
TABLE 04. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2022-2032 ($MILLION)
TABLE 05. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2022-2032 ($MILLION)
TABLE 06. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 08. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 09. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 13. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. RADIOPHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 25. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 29. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 37. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 42. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 46. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 50. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 54. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 58. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 71. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 73. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 75. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 79. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 83. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 94. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 95. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 98. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 100. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. CURIUM PHARMA: KEY EXECUTIVES
TABLE 116. CURIUM PHARMA: COMPANY SNAPSHOT
TABLE 117. CURIUM PHARMA: PRODUCT SEGMENTS
TABLE 118. CURIUM PHARMA: PRODUCT PORTFOLIO
TABLE 119. CURIUM PHARMA: KEY STRATERGIES
TABLE 120. CARDINAL HEALTH INC.: KEY EXECUTIVES
TABLE 121. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
TABLE 122. CARDINAL HEALTH INC.: PRODUCT SEGMENTS
TABLE 123. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
TABLE 124. CARDINAL HEALTH INC.: KEY STRATERGIES
TABLE 125. GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
TABLE 126. GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
TABLE 127. GENERAL ELECTRIC COMPANY: PRODUCT SEGMENTS
TABLE 128. GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
TABLE 129. GENERAL ELECTRIC COMPANY: KEY STRATERGIES
TABLE 130. ISO-TEX DIAGNOSTICS, INC: KEY EXECUTIVES
TABLE 131. ISO-TEX DIAGNOSTICS, INC: COMPANY SNAPSHOT
TABLE 132. ISO-TEX DIAGNOSTICS, INC: PRODUCT SEGMENTS
TABLE 133. ISO-TEX DIAGNOSTICS, INC: PRODUCT PORTFOLIO
TABLE 134. LANTHEUS HOLDINGS, INC.: KEY EXECUTIVES
TABLE 135. LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 136. LANTHEUS HOLDINGS, INC.: PRODUCT SEGMENTS
TABLE 137. LANTHEUS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 138. LANTHEUS HOLDINGS, INC.: KEY STRATERGIES
TABLE 139. SIEMENS AG: KEY EXECUTIVES
TABLE 140. SIEMENS AG: COMPANY SNAPSHOT
TABLE 141. SIEMENS AG: PRODUCT SEGMENTS
TABLE 142. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 143. JUBILANT PHARMOVA LIMITED: KEY EXECUTIVES
TABLE 144. JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT
TABLE 145. JUBILANT PHARMOVA LIMITED: PRODUCT SEGMENTS
TABLE 146. JUBILANT PHARMOVA LIMITED: SERVICE SEGMENTS
TABLE 147. JUBILANT PHARMOVA LIMITED: PRODUCT PORTFOLIO
TABLE 148. JUBILANT PHARMOVA LIMITED: KEY STRATERGIES
TABLE 149. NOVARTIS AG: KEY EXECUTIVES
TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 151. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 152. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 153. NOVARTIS AG: KEY STRATERGIES
TABLE 154. BAYER AG: KEY EXECUTIVES
TABLE 155. BAYER AG: COMPANY SNAPSHOT
TABLE 156. BAYER AG: PRODUCT SEGMENTS
TABLE 157. BAYER AG: PRODUCT PORTFOLIO
TABLE 158. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 159. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 160. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 161. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 162. ELI LILLY AND COMPANY: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALRADIOPHARMACEUTICALS MARKET
FIGURE 10. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. RADIOPHARMACEUTICALS MARKET, BY END USER, 2022(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. RADIOPHARMACEUTICALS MARKET BY REGION, 2022
FIGURE 28. U.S. RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 29. CANADA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 30. MEXICO RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 31. GERMANY RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 32. FRANCE RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 33. UK RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 34. ITALY RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 35. SPAIN RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 37. JAPAN RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 38. CHINA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 39. AUSTRALIA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 40. INDIA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 43. BRAZIL RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 44. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 45. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 46. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, 2022-2032 ($MILLION)
FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 51. COMPETITIVE DASHBOARD
FIGURE 52. COMPETITIVE HEATMAP: RADIOPHARMACEUTICALS MARKET
FIGURE 53. TOP PLAYER POSITIONING, 2022
FIGURE 54. CARDINAL HEALTH INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 55. CARDINAL HEALTH INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. CARDINAL HEALTH INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. GENERAL ELECTRIC COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 58. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. GENERAL ELECTRIC COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. LANTHEUS HOLDINGS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. LANTHEUS HOLDINGS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. JUBILANT PHARMOVA LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 72. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security